Leishmaniasis Clinical Trial
The investigators will compare the common treatment for cutaneous leishmaniasis with
intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.
Outcome will be final scar appearance assesd by two dermatologist and pain measurement by
VAS.
20 healthy patients diagnosed will cutaneous leishmaniasis with more than one lesion will be
recruited.
Half of the lesions will be treated with intra-lesional injections of Pentostam, and the
other half by CO2 laser with topical application of Pentostam.
Each lesion will recieve 3 treatments, one month apart between treatments. The patients will
scale pain level of each treatment. Final scar appearance will be assessed by two
dermatologists, without knowing what treatment was applied to each lesion.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT04504435 -
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT00004755 -
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
|
Phase 2 | |
| Completed |
NCT00657618 -
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
|
Phase 1/Phase 2 | |
| Completed |
NCT04512742 -
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
|
N/A | |
| Recruiting |
NCT00344188 -
Diagnosis and Treatment of Leishmania Infections
|
||
| Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
| Recruiting |
NCT06307171 -
Human Leishmaniasis: Antigen Recognition Pattern and Study of New Potential Biomarkers
|
N/A | |
| Completed |
NCT01751048 -
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
|
Phase 1 | |
| Terminated |
NCT06124144 -
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
|
Phase 1 | |
| Completed |
NCT00662012 -
Sodium Stibogluconate Treatment of Leishmaniasis
|
Phase 2 | |
| Completed |
NCT03993093 -
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
|
||
| Recruiting |
NCT03784248 -
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
|
||
| Withdrawn |
NCT02429505 -
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
|
||
| Completed |
NCT01377974 -
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
|
Phase 2 | |
| Completed |
NCT02656797 -
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT01484548 -
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT01300975 -
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT03294161 -
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
|
Phase 2 | |
| Completed |
NCT00401557 -
Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection
|